Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma

BACKGROUND: Assess benefit of salvage bevacizumab (BEV) at time of symptomatic progression in patients with refractory glioblastoma (GBM). METHODS: Patients managed with adjuvant long course chemo-radiation therapy for GBM were entered into a prospective database. At chemorefractory symptomatic prog...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Cuncannon, Moire, Wong, Matthew, Jayamanne, Dasantha, Guo, Linxin, Cove, Nicola, Wheeler, Helen, Back, Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6518639/
https://ncbi.nlm.nih.gov/pubmed/31088401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5678-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky